Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSN2898 in acne vulgaris
NCT02796066Phase 2Withdrawn
- Sponsor
- Thesan Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of TSN2898 in acne vulgaris (4 arms), sponsored by Thesan Pharmaceuticals. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 12 weeks. Planned start Jun 2016; status: withdrawn.
02
Drugs
TSN2898
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02796066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02796066.